Cancer Research 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 1634-1639, March 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pour, P. M.
Right arrow Articles by Carlson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pour, P. M.
Right arrow Articles by Carlson, K.

Inhibition of Streptozotocin-induced Islet Cell Tumors and N-Nitrosobis(2-oxopropyl)amine-induced Pancreatic Exocrine Tumors in Syrian Hamsters by Exogenous Insulin1

Parviz M. Pour2, Katherine Kazakoff and Kim Carlson

The Eppley Institute and Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68105-1065

The effects of streptozotocin (SZ) and N-nitrosobis(2-oxopropyl)amine (BOP), separately or in combination, on the pancreas, common duct, and gallbladder, all target tissues of BOP, were studied in Syrian golden hamsters. Groups of hamsters were treated with either a single dose (20 mg/kg body weight) of BOP (BOP group), or a single i.p. dose (50 mg/kg body weight) of SZ and 14 days later with a single s.c. injection of the same dose of BOP (SZ + BOP group). Another group of animals was treated similarly with BOP and SZ except that they received twice daily injections of insulin, beginning 1 day after SZ administration and for the duration of the experiment (52 weeks) (SZ + insulin + BOP group). The control group consisted of hamsters treated with a single dose of BOP and daily doses of insulin (insulin + BOP group). Hamsters treated with SZ recovered spontaneously from their diabetes, although the mortality was high (86%). BOP treatment inhibited the diabetogenic effects of SZ in both SZ + BOP and SZ + insulin + BOP groups and reduced the mortality to 43 and 74%, respectively. SZ pretreatment inhibited the incidence of BOP-induced pancreatic ductal/ductular cell carcinomas in the SZ + BOP group (P < 0.01); this protective effect of SZ on carcinoma development was potentiated by additional treatment with insulin (SZ + insulin + BOP group, P < 0.001). Although the frequency of BOP-induced tumors in the gallbladder (all polyps) was not altered by either SZ or insulin, the frequency of the common duct polyps was significantly lower in the SZ + insulin + BOP group than in the BOP group (P < 0.005). Hamsters in the SZ, SZ + BOP, and SZ + insulin + BOP groups developed islet cell adenomas (insulomas). However, the SZ + insulin + BOP group had significantly fewer insulomas than in the SZ + BOP group (P < 0.0005). The overall data confirm the inhibitory effect of SZ on BOP-induced pancreatic cancer and suggest that this effect is related to the diabetic condition of hamsters rather than insulin deficiency and that intact islets appear to be prerequisite for exocrine pancreatic cancer induction by BOP. On the other hand, the inhibitory action of insulin on insuloma induction by SZ and on ductal/ductular cancer induction by BOP seems to be related to the suppressive effect of this hormone on ß-cell and ductal/ductular cell replication, respectively.

1 Supported by Grant CA38922, Laboratory Core Grant CA36727, National Cancer Institute/NIH, and SIG-16, American Cancer Society.

2 To whom requests for reprints should be addressed, at The Eppley Institute for Research in Cancer, University of Nebraska Medical Center, 42nd and Dewey Avenue, Omaha, NE 68105-1065.

Received 5/12/89. Revised 8/ 7/89. Revised 11/13/89. Accepted 11/15/89.




This article has been cited by other articles:


Home page
Am J EpidemiolHome page
R. Z. Stolzenberg-Solomon, K. Adams, M. Leitzmann, C. Schairer, D. S. Michaud, A. Hollenbeck, A. Schatzkin, and D. T. Silverman
Adiposity, Physical Activity, and Pancreatic Cancer in the National Institutes of Health-AARP Diet and Health Cohort
Am. J. Epidemiol., March 1, 2008; 167(5): 586 - 597.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
O. Strobel, Y. Dor, A. Stirman, A. Trainor, C. Fernandez-del Castillo, A. L. Warshaw, and S. P. Thayer
beta cell transdifferentiation does not contribute to preneoplastic/metaplastic ductal lesions of the pancreas by genetic lineage tracing in vivo
PNAS, March 13, 2007; 104(11): 4419 - 4424.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
R. Z. Stolzenberg-Solomon, B. I. Graubard, S. Chari, P. Limburg, P. R. Taylor, J. Virtamo, and D. Albanes
Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers
JAMA, December 14, 2005; 294(22): 2872 - 2878.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. Schmied, G. Liu, M.P. Moyer, I.S.B. Hernberg, W. Sanger, S. Batra, and P. M. Pour
Induction of adenocarcinoma from hamster pancreatic islet cells treated with N-nitrosobis(2-oxopropyl)amine in vitro
Carcinogenesis, February 1, 1999; 20(2): 317 - 324.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.